Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Debiopharm International SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Debiopharm International SA, Medical Devices Deals, 2011 to YTD 2017 10
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Debiopharm International SA, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 14
Debiopharm International Acquires FibroTrap Sample Processing Technology from Spinomix 15
Debiopharm Group Acquires Antibiotic Clinical Assets and Technology Platform From Affinium 16
Venture Financing 18
Spinomix Raises US$3 Million In Series A Financing 18
Biocartis Raises US$44.7 Million In Series D Financing 19
Biocartis Secures US$96 Million In Series C Financing Round 21
Partnerships 23
Debiopharm Partners with Merck and Pfizer 23
Debiopharm Enters into Distribution Agreement with Arbor Pharma 24
Debiopharm International Enters into Agreement with EORTC 25
United Labs Enters into Distribution Agreement with Debiopharm International 26
Debiopharm Enters into Agreement with Solid Biosciences 27
Atheris Labs Enters Into Agreement With Debiopharm For Debio 0826 Optimization 28
Experimental Therapeutics And Debiopharm Enter Into Agreement To Develop Epigenetic Oncology Target 29
Debiopharm International And TCG Lifesciences Enter Into Research Agreement To Develop Antibiotics 30
Cenix BioScience And Debiopharm Enter Into Agreement To Develop Drug Candidates 31
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 32
Debiopharm Group Enters Into Co-Development Agreement With Marina Biotech 33
Licensing Agreements 34
Debiopharm International Enters into Licensing Agreement with Almac Discovery 34
Evotec Enters Into Licensing Agreement With Debiopharm 35
Shasun Pharma Enters Into Licensing Agreement With Debiopharm 36
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 37
Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 38
Debiopharm Enters Into Licensing Agreement With Ascenta Therapeutics For AT-406 39
Debiopharm Enters Into Licensing Agreement With Yale University For Debio 1036 40
Debiopharm Enters Into Option Licensing Agreement With Aurigene Discovery Technologies For Debio 1142 41
Debiopharm International SA – Key Competitors 42
Debiopharm International SA – Key Employees 43
Debiopharm International SA – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 45
Government and Public Interest 45
Jul 25, 2017: Debiopharm International Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to Fight Drug Resistant Gonorrhea 45
Product News 46
10/25/2016: Debiopharm International Reaches Important Development Milestones for its Staphylococcus-selective antibiotic Debio 1450 46
04/08/2016: Debiopharm International to present the latest findings on Debio 1450 at ECCMID 47
01/10/2016: ImmunoGen Announces Update on IMGN529 and Anticipated 2016 Events in Advance of J.P. Morgan Healthcare Conference 48
Clinical Trials 50
Jan 10, 2017: Debiopharm International Announces positive Phase 2 Clinical Trial with Debio 1450 in ABSSSI patients 50
Apr 15, 2016: Debiopharm International announces presentation at AACR of non-clinical data relating to its targeted investigational compound Debio 1347/CH5183284, a selective FGFR 1,2,3 inhibitor 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52
Debiopharm International SA, Pharmaceuticals & Healthcare, Key Facts 2
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Debiopharm International SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Debiopharm International SA, Deals By Therapy Area, 2011 to YTD 2017 9
Debiopharm International SA, Medical Devices Deals, 2011 to YTD 2017 10
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 14
Debiopharm International Acquires FibroTrap Sample Processing Technology from Spinomix 15
Debiopharm Group Acquires Antibiotic Clinical Assets and Technology Platform From Affinium 16
Spinomix Raises US$3 Million In Series A Financing 18
Biocartis Raises US$44.7 Million In Series D Financing 19
Biocartis Secures US$96 Million In Series C Financing Round 21
Debiopharm Partners with Merck and Pfizer 23
Debiopharm Enters into Distribution Agreement with Arbor Pharma 24
Debiopharm International Enters into Agreement with EORTC 25
United Labs Enters into Distribution Agreement with Debiopharm International 26
Debiopharm Enters into Agreement with Solid Biosciences 27
Atheris Labs Enters Into Agreement With Debiopharm For Debio 0826 Optimization 28
Experimental Therapeutics And Debiopharm Enter Into Agreement To Develop Epigenetic Oncology Target 29
Debiopharm International And TCG Lifesciences Enter Into Research Agreement To Develop Antibiotics 30
Cenix BioScience And Debiopharm Enter Into Agreement To Develop Drug Candidates 31
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 32
Debiopharm Group Enters Into Co-Development Agreement With Marina Biotech 33
Debiopharm International Enters into Licensing Agreement with Almac Discovery 34
Evotec Enters Into Licensing Agreement With Debiopharm 35
Shasun Pharma Enters Into Licensing Agreement With Debiopharm 36
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 37
Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 38
Debiopharm Enters Into Licensing Agreement With Ascenta Therapeutics For AT-406 39
Debiopharm Enters Into Licensing Agreement With Yale University For Debio 1036 40
Debiopharm Enters Into Option Licensing Agreement With Aurigene Discovery Technologies For Debio 1142 41
Debiopharm International SA, Key Competitors 42
Debiopharm International SA, Key Employees 43
Debiopharm International SA, Subsidiaries 44